Autolus Therapeutics announced clinical data on obe-cel, a T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) with extramedullary disease (EMD), at the ASCO 2026 meeting. The Phase Ib/II FELIX study showed a 59% overall response rate and a median duration of response of 42.6 months in patients with EMD, a group typically facing poor outcomes. This suggests obe-cel could be a valuable treatment option for this difficult-to-treat population. The data highlights obe-cel's favorable benefit-risk profile and supports further development and use in high-risk B-ALL patients.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
